Tevogen Bio Holdings Inc Dossier
Qualitative Analysis
Business overview
Tevogen Bio Holdings Inc. (NASDAQ: TVGN) is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, precision, genetically unmodified T cell therapies. The company leverages its proprietary ExacTcell™ platform to harness CD8+ cytotoxic T lymphocytes (CTLs) to target infectious diseases, cancers, and neurological disorders. Its lead clinical product candidate, TVGN 489, is designed to address unmet needs in high-risk, immunocompromised, and elderly COVID-19 patients, as well as individuals suffering from Long COVID. Additionally, the company has established Tevogen.AI, an artificial intelligence initiative designed to accelerate drug target detection, optimize clinical trial design, and reduce drug development failure rates.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A strategic business area designed to support Tevogen's evolution into a broader, revenue-generating healthcare enterprise. The initiative focuses on evaluating and executing acquisition opportunities involving a Management Services Organization (MSO) and a Contract Research Organization (CRO).
Expected impact: Aims to generate approximately $100 million in combined annual revenue and support long-term financial self-sufficiency.
An artificial intelligence initiative developed in collaboration with technology leaders Microsoft and Databricks. It leverages cloud and data services to predict the proteome for any given protein-HLA combination, accelerating drug discovery and optimizing clinical trial design.
Expected impact: Aims to significantly reduce drug development failure rates, lower R&D costs, and support rapid therapeutic discovery.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides cloud infrastructure and data tools (such as Microsoft Fabric) to power Tevogen.AI's predictive drug discovery models.
Terms: Not publicly disclosed.
Enables advanced data engineering and machine learning capabilities to support the PredicTcell™ platform.
Terms: Not publicly disclosed.